Recently, in a non‐small cell lung cancer harboring an EGFR mutation, a large retrospective cohort study showed that progression‐free survival was longer in patients who received statins to treat dyslipidemia, for example, than in patients who received EGFR‐TKI alone,45 suggesting that the relationship between molecular targeted therapies and the control of lipid metabolism is of interest. This evidence concerns the gene EGFR and metabolic syndrome.